ESC/EASD Joint Guidelines on Diabetes and Cardiovascular Diseases

被引:0
|
作者
Motz, Wolfgang [1 ]
Doerr, Rolf [2 ]
机构
[1] Klin Grp Dr Guth GmbH & Co KG, Klinikum Karlsburg, D-17495 Karlsburg, Germany
[2] Akad Lehrpraxisklin TU, Praxisklin Herz & Gefasse Kardiol Angiol Radiol N, Dresden, Germany
关键词
Diabetes mellitus; Prediabetes; Cardiovascular diseases; Coronary heart disease; Coronary artery disease equivalent; Risk factors; Coronary revascularization; CORONARY-HEART-DISEASE; DRUG-ELUTING STENTS; ELEVATION MYOCARDIAL-INFARCTION; SUDDEN CARDIAC DEATH; BLOOD-PRESSURE; CLINICAL-OUTCOMES; GLUCOSE-TOLERANCE; RISK-FACTORS; FOLLOW-UP; MELLITUS;
D O I
10.1007/s00059-009-3203-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ESC/EASD (European Society of Cardiology/European Association for the Study of Diabetes) joint Guidelines on diabetes, pre-diabetes, and cardiovascular diseases have, for the first time, addressed diabetes mellitus and cardiovascular diseases (CVD) as a pathophysiological entity in Europe. Based on these guidelines, diabetes mellitus is regarded from the outset to be a cardiovascular disease, whose life-threatening complications myocardial infarction and stroke can only be avoided by an interdisciplinary concerted action. The most important information of these guidelines for the interdisciplinary cooperation of primary-care physicians, diabetologists and cardiologists are the postulations that patients with the main diagnosis diabetes mellitus with or without known CVD should, at regular intervals, be referred to a cardiologist, and patients with the main diagnosis CVD with or without diabetes mellitus should, at regular intervals, be referred to a diabetologist. Of fundamental importance is the prevention of diabetes and CVD by a comprehensive lifestyle modification including smoking cessation, regular physical activity and weight control, flanked by an evidence-based drug therapy. Within the framework of a multimodal risk management, an optimal antihypertensive therapy of a concomitant elevated blood pressure; a statin therapy in case of elevated LDL cholesterol or regardless of an elevated LDL in proven CVD; ACE inhibitors, angiotensin II receptor blockers, or beta-blockers in case of heart failure; and an anticoagulant therapy for the prevention of cardioembolic stroke in patients with atrial fibrillation all have class I recommendations. Concerning the preferred coronary revascularization procedure in diabetics, today no rigid general recommendation can be given in favor of or against coronary bypass surgery, or in favor of or against percutaneous coronary intervention. The decision for a specific revascularization procedure should, in any case, be based on a detailed analysis of the individual coronary anatomy.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [41] The new ESC guidelines 2021 on prevention of cardiovascular diseases Appeal for prevention
    Fegers-Wustrow, Isabel
    Wimbauer, Fritz
    Halle, Martin
    HERZ, 2022, 47 (01) : 55 - 62
  • [42] Screening asymptomatic patients with diabetes for coronary stenoses suitable for revascularisation: a retrospective evaluation of ESC-EASD guidelines
    Berkane, N.
    Cosson, E.
    Pinto, S.
    Ciunganu, T.
    Valensi, P.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S427 - S427
  • [43] Clinical Practice Guides ESC 2019 guide on diabetes, prediabetes and cardiovascular disease, in collaboration with the European Association for the Study of Diabetes (EASD)
    Cosentino, Francesco
    Grant, Peter J.
    Aboyans, Victor
    Bailey, Clifford J.
    Ceriello, Antonio
    Delgado, Victoria
    Federici, Massimo
    Filippatos, Gerasimos
    Grobbee, Diederick E.
    Hansen, Tina Birgitte
    Huikuri, Heikki, V
    Johansson, Isabelle
    Juni, Peter
    Lettino, Maddalena
    Marx, Nikolaus
    Mellbin, Linda G.
    Ostgren, Carl J.
    Rocca, Bianca
    Roffi, Marco
    Sattar, Naveed
    Seferovic, Petar M.
    Sousa-Uva, Miguel
    Valensi, Paul
    Wheeler, David C.
    REVISTA ESPANOLA DE CARDIOLOGIA, 2020, 73 (05):
  • [44] ESC-Guidelines 2016-Prevention of Cardiovascular Diseases in Clinical Practice
    Wienbergen, Harm
    Hambrecht, Rainer
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (03) : 189 - 192
  • [45] Validation of the ESC/EASD cardiovascular risk stratification model in diabetic patients
    Prausmueller, S.
    Michael, R.
    Arfsten, H.
    Spinka, G.
    Wurm, R.
    Neuhold, S.
    Bartko, P. E.
    Goliasch, G.
    Strunk, G.
    Noemi, P.
    Clodi, M.
    Huelsmann, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S174 - S175
  • [46] Validation of the ESC/EASD cardiovascular risk stratification model in diabetic patients
    Prausmueller, S.
    Resl, M.
    Arfsten, H.
    Spinka, G.
    Wurm, R.
    Neuhold, S.
    Bartko, P.
    Goliasch, G.
    Strunk, G.
    Pavo, N.
    Clodi, M.
    Huelsmann, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2902 - 2902
  • [47] ESC 2018 guidelines on the treatment of cardiovascular diseases in pregnancy: what's new?
    Presbitero, Patrizia
    GIORNALE ITALIANO DI CARDIOLOGIA, 2019, 20 (09) : 469 - 474
  • [48] 'Ten Commandments' of the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
    Regitz-Zagrosek, Vera
    EUROPEAN HEART JOURNAL, 2018, 39 (35) : 3269 - 3269
  • [49] What is new in the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy?
    Irene M. Lang
    Wiener klinische Wochenschrift, 2020, 132 : 69 - 72
  • [50] What is new in the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy?
    Lang, Irene M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 (3-4) : 69 - 72